Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Office Manager (m/w/d)
      • Controller (m/w/d)

Clinical Development

  • Home
  • R&D
  • Clinical Development

Clinical development - Chronic inflammation

The role of C5a in chronic inflammation has become increasingly clear in recent years, making C5a an attractive target for chronic and autoimmune inflammatory diseases. This is largely because of its ability to skew T-cell responses, causing a substantial imbalance and shift towards pro-inflammatory T-cell responses. In line with this finding, many chronic inflammatory diseases are burdened by flare phases with intensified inflammation causing tissue damage, which is often promoted by auto-activation of neutrophils.


Blocking C5a delivers various potentially beneficial effects in chronic inflammatory diseases. Blocking the C5a / C5aR signaling axis has been shown to re-establish T-cell balance by increasing regulatory T-cells and decreasing pro-inflammatory Th-17 and Th-1 responses. C5a blockade also offers a strong potential to control neutrophil activation in addition to its other important anti-inflammatory mechanisms.

 

Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases with high unmet medical need. These indications include:

 

  1.      Hidradenitis Suppurativa (HS)
     
  2.      ANCA-associated Vasculitis (AAV)
     
  3.      Pyoderma Gangraenosum (PG)
     
  4.     COVID-19
     
  5.     cSCC

 

Studies in other indications, including in oncology, are planned.

Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals